DE60116642D1 - Verbindungen mit cytochrom p450ra1 hemmenden aktivität - Google Patents

Verbindungen mit cytochrom p450ra1 hemmenden aktivität

Info

Publication number
DE60116642D1
DE60116642D1 DE60116642T DE60116642T DE60116642D1 DE 60116642 D1 DE60116642 D1 DE 60116642D1 DE 60116642 T DE60116642 T DE 60116642T DE 60116642 T DE60116642 T DE 60116642T DE 60116642 D1 DE60116642 D1 DE 60116642D1
Authority
DE
Germany
Prior art keywords
compounds
p450ra1
cytochrom
hardening activity
hardening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60116642T
Other languages
English (en)
Other versions
DE60116642T2 (de
Inventor
Jayasree Vasudevan
Alan T Johnson
Dehua Huang
Liming Wang
Roshantha A Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/651,003 external-priority patent/US6303785B1/en
Priority claimed from US09/651,004 external-priority patent/US6369261B1/en
Priority claimed from US09/651,234 external-priority patent/US6387951B1/en
Priority claimed from US09/651,564 external-priority patent/US6380256B1/en
Priority claimed from US09/651,235 external-priority patent/US6252090B1/en
Priority claimed from US09/651,001 external-priority patent/US6291677B1/en
Priority claimed from US09/651,566 external-priority patent/US6369225B1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE60116642D1 publication Critical patent/DE60116642D1/de
Publication of DE60116642T2 publication Critical patent/DE60116642T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE60116642T 2000-08-29 2001-08-14 Verbindungen mit cytochrom p450ra1 hemmenden aktivität Expired - Fee Related DE60116642T2 (de)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US651235 2000-08-29
US651564 2000-08-29
US651003 2000-08-29
US651234 2000-08-29
US651566 2000-08-29
US09/651,004 US6369261B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,234 US6387951B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,564 US6380256B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,235 US6252090B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,001 US6291677B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US651001 2000-08-29
US651004 2000-08-29
US09/651,003 US6303785B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,566 US6369225B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
PCT/US2001/025443 WO2002018361A2 (en) 2000-08-29 2001-08-14 Compounds having activity as inhibitors of cytochrome p450rai

Publications (2)

Publication Number Publication Date
DE60116642D1 true DE60116642D1 (de) 2006-04-06
DE60116642T2 DE60116642T2 (de) 2006-11-09

Family

ID=27569871

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60116642T Expired - Fee Related DE60116642T2 (de) 2000-08-29 2001-08-14 Verbindungen mit cytochrom p450ra1 hemmenden aktivität

Country Status (9)

Country Link
EP (1) EP1366036B1 (de)
JP (1) JP2004507531A (de)
AT (1) ATE315558T1 (de)
AU (2) AU8647101A (de)
CA (1) CA2420869A1 (de)
DE (1) DE60116642T2 (de)
ES (1) ES2256288T3 (de)
HK (1) HK1059439A1 (de)
WO (1) WO2002018361A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US6740676B2 (en) * 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EA011385B1 (ru) 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
BRPI0413923A (pt) 2003-08-29 2006-11-07 Ono Pharmaceutical Co composto capaz de ligar o receptor de s1p e uso farmacêutico do mesmo
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
ATE541830T1 (de) 2004-12-13 2012-02-15 Ono Pharmaceutical Co Aminocarbonsäurederivat und dessen medizinische verwendung
KR20070114762A (ko) 2005-02-24 2007-12-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료를 위한 ｐｇｄ2 수용체 길항제
AU2011332198A1 (en) * 2010-11-24 2013-07-11 Allergan, Inc. Modulators of S1P receptors
CA2848540A1 (en) 2011-09-15 2013-03-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
SI3204357T1 (sl) * 2014-10-10 2022-05-31 High Force Research Limited Fluorescentni sintetični retinoidi
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0130795B1 (de) * 1983-07-05 1988-11-23 Pfizer Inc. Karbonsäure-Derivate verwendbar bei der Verhütung der Zersetzung von Knorpeln
ZA875052B (en) * 1986-07-11 1989-03-29 Du Pont Angiotensin ii receptor blocking imidazoles
US5089509A (en) * 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5015658A (en) * 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US5045551A (en) * 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5023341A (en) * 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5202471A (en) * 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
US5134159A (en) * 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
EP0800517A1 (de) * 1994-12-29 1997-10-15 Allergan Acetylen-derivate substituiert mit 5-oder 8-substituierten tetrahydronaphthyl oder dihydronaphthyl sowie mit aryl-oder heteroaryl-gruppen mit retinoid artiger wirkung
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity

Also Published As

Publication number Publication date
AU2001286471B2 (en) 2006-09-07
AU8647101A (en) 2002-03-13
JP2004507531A (ja) 2004-03-11
EP1366036B1 (de) 2006-01-11
HK1059439A1 (en) 2004-07-02
ATE315558T1 (de) 2006-02-15
EP1366036A2 (de) 2003-12-03
WO2002018361A2 (en) 2002-03-07
ES2256288T3 (es) 2006-07-16
WO2002018361A3 (en) 2003-07-31
CA2420869A1 (en) 2002-03-07
DE60116642T2 (de) 2006-11-09

Similar Documents

Publication Publication Date Title
DE60116642D1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
WO2002026727A3 (en) Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai
DE50014190D1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
DE60115842D1 (de) Ventilanordnung
NO20002440L (no) Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet
ATE395052T1 (de) Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
DE60143901D1 (de) Antisense-modulation der clusterinexpression
SG146682A1 (en) Modulation of eif4e expression
ID30237A (id) KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
DK1301201T3 (da) Behandling af glycogenosis type II
DE60026152D1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
DE60322121D1 (de) Zusammensetzung zur verabreichung von eisen für die behandlung des unruhigen beinsyndroms
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
ATE298246T1 (de) Aktiviertes protein c zur behandlung von pankreatitis
ATE427745T1 (de) Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
NO955258L (no) Medisinsk anvendelse av enzymer
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
HUP0103660A2 (hu) Mikróbaeredetű hialuronsavbontó enzimet tartalmazó gyógyászati készítmény
ATE534399T1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
ATE345121T1 (de) Verwendung von konjugierter linolsäure zur behandlung der erkältung
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee